About: Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity
Creator	Wu, Alan Stramer, Susan Hightower, Allen Levine, Andrew Bapat, Sagar Beckerdite, Erica Bern, Caryn Esensten, Jonathan Goldgof, Gregory Kastner, Shannon Lacanienta, Noreen Lynch, Kara Shy, Brian Whitman, Jeffrey
Source	MedRxiv
abstract	Background: SARS-CoV-2 infection can be detected indirectly by measuring the host immune response. Anti-viral antibody concentrations generally correlate with host protection and viral neutralization, but in rare cases, antibodies can promote disease progression. Elucidation of the kinetics and magnitude of the SARS-CoV-2 antibody response is essential to understand the pathogenesis of COVID-19 and identify potential therapeutic targets. Methods: Sera (n=533) from patients with RT-PCR confirmed COVID-19 (n=153) were tested using a high-throughput quantitative IgM and IgG assay that detects antibodies to the spike protein receptor binding domain and nucleocapsid protein. Individual and serial samples covered the time of initial diagnosis, during the disease course, and following recovery. We evaluated antibody kinetics and correlation between magnitude of the response and disease severity. Results: Patterns of SARS-CoV-2 antibody production varied considerably. Among 52 patients with 3 or more serial specimens, 44 (84.6%) and 42 (80.8%) had observed IgM and IgG seroconversion at a median of 8 and 10 days, respectively. Compared to those with milder disease, peak measurements were significantly higher for patients admitted to the intensive care unit for all time intervals between 6 and 20 days for IgM, and all intervals after 5 days for IgG. Conclusions: High sensitivity assays with a robust dynamic range provide a comprehensive picture of host antibody response to SARS-CoV-2. IgM and IgG responses were significantly higher in patients with severe than mild disease. These differences may affect strategies for seroprevalence studies, therapeutics and vaccine development.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1101/2020.06.03.20121525
has license	medrxiv
sha1sum (hex)	aa412a2dce26caa77be24e32fe6832b1ed6e4350
schema:url	https://doi.org/10.1101/2020.06.03.20121525
resource representing a document's title	Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity
resource representing a document's body	covid:aa412a2dce26caa77be24e32fe6832b1ed6e4350#body_text
is schema:about of	named entity 'Background' named entity 'PATHOGENESIS' named entity 'DETECTED' named entity 'IDENTIFY' named entity 'RARE' named entity 'HOST' named entity 'TARGETS' named entity 'SARS-COV-2 ANTIBODY' named entity 'immune response' named entity 'infection' named entity 'promote' named entity 'antibody response' named entity 'COVID' named entity 'antibodies' named entity 'antibody' named entity 'antibodies' named entity 'Antibodies' named entity 'ICU' named entity 'ICU' named entity 'SAS Institute Inc.' named entity 'antibody' named entity 'symptom' named entity 'seroconversion' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'RFU' named entity 'IgM' named entity 'Antibody' named entity 'hemolysis' named entity 'IgM' named entity 'IgG' named entity 'ICU' named entity 'antibodies' named entity 'San Francisco' named entity 'follow-up' named entity 'follow-up' named entity 'ICU' named entity 'RT-PCR' named entity 'ICU' named entity 'ICU' named entity 'incomplete nature' named entity 'enzyme immunoassay' named entity 'co-morbidities' named entity 'ICU' named entity 'symptomatic infection' named entity 'medRxiv' named entity 'antibody response' named entity 'chemiluminescence' named entity 'serum samples' named entity 'medRxiv' named entity 'University of California, San Francisco' named entity 'Serological testing' named entity 'cumulative incidence' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'ICU' named entity 'IgG' named entity 'ICU' named entity 'Chi Square test' named entity 'IgG' named entity 'seroconversion' named entity 'SARS-CoV-2' named entity 'neutralizing antibodies' named entity 'ELISAs' named entity 'COVID-19 pandemic' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'ICU' named entity 'epidemiological modeling' named entity 'ICU' named entity 'convalescent plasma' named entity 'intensive care unit'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software